Viral Proteases as Targets for Drug Design

Author(s): Marcin Skorenski, Marcin Sienczyk

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 6 , 2013

Become EABM
Become Reviewer
Call for Editor


In order to productively infect a host, viruses must enter the cell and force host cell replication mechanisms to produce new infectious virus particles. The success of this process unfortunately results in disease progression and, in the case of infection with many viral species, may cause mortality. The discoveries of Louis Pasteur and Edward Jenner led to one of the greatest advances in modern medicine - the development of vaccines that generate long-lasting memory immune responses to combat viral infection. Widespread use of vaccines has reduced mortality and morbidity associated with viral infection and, in some cases, has completely eradicated virus from the human population. Unfortunately, several viral species maintain a significant ability to mutate and “escape” vaccine-induced immune responses. Thus, novel anti-viral agents are required for treatment and prevention of viral disease. Targeting proteases that are crucial in the viral life cycle has proven to be an effective method to control viral infection, and this avenue of investigation continues to generate anti-viral treatments. Herein, we provide the reader with a brief history as well as a comprehensive review of the most recent advances in the design and synthesis of viral protease inhibitors.

Keywords: Viral proteases, protease inhibitors, HIV-1, HCV, Flaviviridae, SARS, Herpesviridae, Adenoviridae.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 17 December, 2012
Page: [1126 - 1153]
Pages: 28
DOI: 10.2174/1381612811319060013
Price: $65

Article Metrics

PDF: 38